- Report
- April 2025
- 200 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1424EUR$1,600USD£1,253GBP
€1780EUR$2,000USD£1,567GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1068EUR$1,200USD£940GBP
€1335EUR$1,500USD£1,175GBP
- Report
- October 2025
- 195 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- January 2022
- 60 Pages
Global
From €2812EUR$3,160USD£2,475GBP
€3515EUR$3,950USD£3,094GBP
- Report
- May 2024
- 136 Pages
Global
From €4916EUR$5,524USD£4,327GBP
€5783EUR$6,499USD£5,091GBP
- Report
- May 2024
- 130 Pages
Global
From €4916EUR$5,524USD£4,327GBP
€5783EUR$6,499USD£5,091GBP
- Report
- September 2023
- 113 Pages
Global
From €3500EUR$4,213USD£3,189GBP
The Ischemia Drug market is a subset of the Cardiovascular Drugs market, which focuses on drugs used to treat ischemia, a condition caused by reduced blood flow to the heart. Ischemia drugs are used to reduce the risk of heart attack, stroke, and other cardiovascular events. These drugs can be used to treat both acute and chronic ischemia, and can be administered orally, intravenously, or through injections. Common ischemia drugs include antiplatelet agents, anticoagulants, and statins.
Ischemia drugs are widely used in the treatment of cardiovascular diseases, and are an important part of the cardiovascular drugs market. Companies in the Ischemia Drug market include Pfizer, Merck, AstraZeneca, Sanofi, and Bristol-Myers Squibb. Show Less Read more
